Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 mcg of OPN-375 Twice a Day (BID) in Adolescent Subjects With Chronic Rhinosinusitis Without Nasal Polyps

NCT06850805 is registered in ClinicalTrials.gov with Optinose US Inc. as lead sponsor.

NCT NCT06850805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06850805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 mcg of OPN-375 Twice a Day (BID) in Adolescent Subjects With Chronic Rhinosinusitis Without Nasal Polyps
Lead sponsor
Optinose US Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
July 28, 2025
Completion date
October 31, 2028
Enrollment
84 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

chronic rhinosinusitis without nasal polyps